CDEK
← All organizations

Schering-Plough

For profitContributed to NME

Also known as: PT. Schering-Plough. Tbk Indonesia | SCHERING PLOUGH | Subsidiary of Schering-Plough

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jul 1, 1996

First marketed drug

Jan 1, 1971

First NDA

Mar 29, 1977

Last known activity

Apr 1, 2012

Acquired by Merck on Jan 1, 2009

Timeline

1970s

  1. Jan 1, 1971

    Schering-Plough— Founded

  2. Jan 1, 1971

    Plough— Acquired

  3. Jan 1, 1971

    Schering— Acquired

  4. Aug 3, 1979

    methyltestosterone— Marketing Organization

1980s

  1. Jan 1, 1982

    DNAX— Acquired

  2. Jan 27, 1989

    flutamide— NDA Secondary Org

1990s

  1. Jan 1, 1990

    Triton Biosciences— Acquired

  2. Jan 1, 1995

    Canji— Acquired

2000s

  1. Dec 21, 2001

    desloratadine— NDA Organization

  2. Jan 1, 2005

    NeoGenesis Pharmaceuticals— Acquired

  3. Jan 1, 2007

    Koninklijke Zwanenberg Organon— Acquired

  4. Nov 1, 2007

    Organon— Acquired

  5. Jan 1, 2009

    Merck— Acquired By

Drugs by trial phase (132 distinct, 181 trials)

Indications

Approved for

Studied for

Marketed drugs (42)

Subsidiaries (8 direct, 22 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Kenilworth, NJ, US Jan 1, 1971
First NDA
Mar 29, 1977
Last known activity
Apr 1, 2012

Designations held

  • Orphan drug
  • Priority review
  • Accelerated approval